title: Treatment responsiveness in CIDP patients with diabetes is associated with unique electrophysiological characteristics, and not with common criteria for CIDP.
abstract: OBJECTIVE
  Characterize treatment responsiveness in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) patients with diabetes mellitus (DM).
  
  
  METHODS
  We performed a retrospective chart review of CIDP subjects assessed between 1997 and 2013 and compared treatment response rates in those with and without DM, using different sets of criteria.
  
  
  RESULTS
  99 CIDP patients were included, 34 CIDP+DM and 65 CIDP-DM patients, both having similar treatment response rates. CIDP patients fulfilling European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) criteria had higher treatment response rates. Responders fulfilled a higher number of American Academy of Neurology (AAN) and EFNS/PNS criteria and had a higher number of demyelinating features in the total cohort and in CIDP-DM but not in CIDP+DM patients. CIDP+DM responders, however, had unique electrophysiologic characteristics.
  
  
  CONCLUSIONS
  Fulfilling EFNS/PNS and AAN criteria, and higher number of demyelinating features, are associated with higher treatment response rates in CIDP-DM but not in CIDP+DM patients, implying the need for adjusting current criteria to predict treatment response rates in CIDP-DM patients.
authors.affiliation: Department of Medicine, Division of Neurology, University of Toronto, Toronto, Canada.
authors.forename: Alon
authors.initials: A
authors.lastname: Abraham
authors.forename: Ari
authors.initials: A
authors.lastname: Breiner
authors.forename: Hans D
authors.initials: HD
authors.lastname: Katzberg
authors.forename: Leif E
authors.initials: LE
authors.lastname: Lovblom
authors.forename: Bruce A
authors.initials: BA
authors.lastname: Perkins
authors.forename: Vera
authors.initials: V
authors.lastname: Bril
mesh_terms: D000368:Aged; D054316:Biomarkers, Pharmacological / Q000378:metabolism; D048909:Diabetes Complications / Q000628:therapy*; D055724:Electrophysiological Phenomena; D005060:Europe; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000150:complications / Q000628:therapy*; D017410:Practice Guidelines as Topic; D011379:Prognosis; D012189:Retrospective Studies; D016896:Treatment Outcome; D014481:United States
chemical_list: D054316:Biomarkers, Pharmacological
keywords: chronic inflammatory demyelinating polyradiculoneuropathy; criteria; demyelination; diabetic neuropathy; type 1 diabetes; type 2 diabetes